



Clinical trial results:

A Double-Blind, Efficacy and Safety Study of Duloxetine versus Placebo in the Treatment of Children and Adolescents with Generalized Anxiety Disorder

Summary

EudraCT number	2017-001599-46
Trial protocol	Outside EU/EEA
Global end of trial date	03 June 2013

Results information

Result version number	v1 (current)
This version publication date	24 December 2017
First version publication date	24 December 2017

Trial information

Trial identification

Sponsor protocol code	F1J-MC-HMGI
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01226511
WHO universal trial number (UTN)	-
Other trial identifiers	Eli Lilly and Company: 12929

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 June 2013
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	03 June 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 206
Country: Number of subjects enrolled	Mexico: 52
Country: Number of subjects enrolled	South Africa: 23
Worldwide total number of subjects	281
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	128
Adolescents (12-17 years)	144
Adults (18-64 years)	9
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

All Randomized participants from one site were excluded from this results record. All randomized participants from this site were not considered as part of the ITT population & were excluded from Subject Disposition, Baseline characteristics, efficacy and safety analyses due to major quality issues at that site.

Pre-assignment

Screening details:

This study had 4 periods: Screening period (1-week), acute treatment period (10-week, double-blind period with flexible duloxetine dosing), extension treatment (18-week period, of which 16 weeks were open-label treatment with flexible duloxetine dosing), and a taper period (2 weeks recommended at discontinuation from study any point after Week 2).

Period 1

Period 1 title	Acute Treatment period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Duloxetine/Duloxetine

Arm description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Arm type	Experimental
Investigational medicinal product name	Duloxetine
Investigational medicinal product code	
Other name	LY248686, Cymbalta
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

30 to 120 Duloxetine mg administered orally.

Arm title	Placebo/Duloxetine
------------------	--------------------

Arm description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo administered orally.

Number of subjects in period 1^[1]	Duloxetine/Duloxetine	Placebo/Duloxetine
Started	135	137
Completed	104	106
Not completed	31	31
Parent/Caregiver Decision	4	7
Consent withdrawn by subject	10	6
Adverse event, non-fatal	7	6
Lost to follow-up	3	6
Lack of efficacy	2	1
Protocol deviation	5	5

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 39 in Duloxetine/Duloxetine group & 35 Participants in Placebo/Duloxetine group who completed extension treatment period did not enter the taper period.

Period 2

Period 2 title	Extension Treatment Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

18-week treatment period of which 16 weeks were open-label.

Arms

Are arms mutually exclusive?	Yes
Arm title	Duloxetine/Duloxetine

Arm description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Duloxetine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: 30 to 120 mg administered orally.	
Arm title	Placebo/Duloxetine

Arm description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Arm type	Experimental
Investigational medicinal product name	Duloxetine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

30 to 120 mg administered orally.

Number of subjects in period 2	Duloxetine/Duloxetine	Placebo/Duloxetine
Started	104	106
Completed	79	81
Not completed	25	25
Parent/Caregiver Decision	7	8
Consent withdrawn by subject	1	3
Adverse event, non-fatal	8	7
Lost to follow-up	4	3
Lack of efficacy	3	2
Protocol deviation	2	2

Period 3

Period 3 title	Taper Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Duloxetine/Duloxetine

Arm description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Arm type	Experimental
Investigational medicinal product name	Duloxetine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

30 to 120 mg administered orally.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo administered orally.

Arm title	Placebo/Duloxetine
------------------	--------------------

Arm description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Arm type	Placebo
Investigational medicinal product name	Duloxetine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

30 to 120 mg administered orally.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo administered orally.

Number of subjects in period 3^[2]	Duloxetine/Duloxetine	Placebo/Duloxetine
Started	49	55
Completed	44	52
Not completed	5	3
Parent/Caregiver Decision	1	1
Adverse event, non-fatal	1	-
Lost to follow-up	2	2
Protocol deviation	1	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 39 in Duloxetine/Duloxetine group & 35 Participants in Placebo/Duloxetine group who completed extension treatment period did not enter the taper period.

Baseline characteristics

Reporting groups

Reporting group title	Duloxetine/Duloxetine
-----------------------	-----------------------

Reporting group description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group title	Placebo/Duloxetine
-----------------------	--------------------

Reporting group description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group values	Duloxetine/Duloxetine	Placebo/Duloxetine	Total
Number of subjects	135	137	272
Age, Customized Units: participants			
7 - 11 Years	62	66	128
12 - 17 Years	73	71	144
Age continuous Units:	12.55 ± 2.596	12.2 ± 2.904	-
Gender, Male/Female Units:			
Male	65	62	127
Female	70	75	145
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	7	6	13
Asian	1	1	2
Black or African American	9	10	19
White	112	111	223
More than one race	6	9	15
Region of Enrollment Units: Subjects			
United States	98	99	197
Mexico	26	26	52
South Africa	11	12	23

End points

End points reporting groups

Reporting group title	Duloxetine/Duloxetine
-----------------------	-----------------------

Reporting group description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group title	Placebo/Duloxetine
-----------------------	--------------------

Reporting group description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group title	Duloxetine/Duloxetine
-----------------------	-----------------------

Reporting group description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group title	Placebo/Duloxetine
-----------------------	--------------------

Reporting group description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group title	Duloxetine/Duloxetine
-----------------------	-----------------------

Reporting group description:

Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Reporting group title	Placebo/Duloxetine
-----------------------	--------------------

Reporting group description:

Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period

participation received placebo over the 2-week recommended tapering period.

Subject analysis set title	Duloxetine (Acute Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period.	
Subject analysis set title	Placebo (Acute Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period.	
Subject analysis set title	Duloxetine (Acute Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period.	
Subject analysis set title	Placebo (Acute Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period.	
Subject analysis set title	Placebo (Acute Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period.	
Subject analysis set title	Duloxetine/Duloxetine (Extension Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period.	
Subject analysis set title	Placebo/Duloxetine (Extension Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period.	
Subject analysis set title	Duloxetine/Duloxetine (Extension Treatment)
Subject analysis set type	Full analysis
Subject analysis set description: Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period.	

Primary: Change from Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist

End point title	Change from Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist
-----------------	--

End point description:

PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for baseline,

pooled investigator, age category, visit, treatment, treatment*visit, age category*visit, and baseline*visit.

Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline PARS severity score for GAD during the acute treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Primary
End point timeframe:	
Baseline, 10 weeks	

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	133		
Units: units on a scale				
least squares mean (standard error)	-9.7 (\pm 0.502)	-7.05 (\pm 0.5)		

Statistical analyses

Statistical analysis title	Statistical Analysis
Comparison groups	Duloxetine (Acute Treatment) v Placebo (Acute Treatment)
Number of subjects included in analysis	268
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Least squares (LS) mean difference
Point estimate	-2.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.03
upper limit	-1.27
Variability estimate	Standard error of the mean
Dispersion value	0.7

Secondary: Response Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Pediatric Anxiety Rating Scale (PARS) Severity Score for GAD

End point title	Response Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Pediatric Anxiety Rating Scale (PARS) Severity Score for GAD
-----------------	---

End point description:

Response rate was defined as the percentage of participants having a 50% improvement from baseline to endpoint on the PARS severity score for GAD. PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores

for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity.

Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline PARS severity score for GAD [last observation carried forward (LOCF)] during the acute treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
End point timeframe:	
Baseline, 10 weeks	

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	133		
Units: percentage of participants				
number (not applicable)	51	37		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline to 10-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist

End point title	Change from Baseline to 10-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist
-----------------	--

End point description:

PARS severity total score was assessed for all symptoms identified on the PARS symptom checklist. PARS severity total score was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity total scores ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for treatment, pooled investigator, visit, baseline, age category, treatment*visit, baseline*visit, and age category*visit.

Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline PARS severity total score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
End point timeframe:	
Baseline, 10 weeks	

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	133		
Units: units on a scale				
least squares mean (standard error)	-9.15 (\pm 0.479)	-6.36 (\pm 0.477)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline to 10-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale

End point title	Change from Baseline to 10-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale
End point description: The CGI-S scale evaluated the severity of illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for treatment, pooled investigator, visit, baseline, age category, treatment*visit, baseline*visit, and age category*visit.	
Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline CGI-S score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.	
End point type	Secondary
End point timeframe: Baseline, 10 weeks	

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	133		
Units: units on a scale				
least squares mean (standard error)	-1.93 (\pm 0.114)	-1.38 (\pm 0.113)		

Statistical analyses

No statistical analyses for this end point

Secondary: Remission Rate at Endpoint for generalized anxiety disorder (GAD) Using Clinical Global Impressions of Severity (CGI-S) Scale

End point title	Remission Rate at Endpoint for generalized anxiety disorder (GAD) Using Clinical Global Impressions of Severity (CGI-S) Scale
-----------------	---

End point description:

Remission rate was defined as the percentage of participants having a CGI-S score ≤ 2 at endpoint. The CGI-S scale evaluated the severity of illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness.

Analysis Population Description: Randomized participants with at least 1 post-baseline CGI-S score [last observation carried forward (LOCF)] during the acute treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
End point timeframe:	
10 weeks	

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	133		
Units: percentage of participants				
number (not applicable)	45	30		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline to 10-Week Endpoint in the Children's Global Assessment Scale (CGAS)

End point title	Change from Baseline to 10-Week Endpoint in the Children's Global Assessment Scale (CGAS)
-----------------	---

End point description:

The CGAS was a clinician-rated assessment of general functioning. CGAS raw scores ranged from 1 (greatest impairment) to 100 (superior functioning). Lower scores indicated a lower level of functioning and greater impairment. Least squares (LS) mean from an analysis of covariance (ANCOVA) was adjusted for treatment, pooled investigator, baseline, and age category.

Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline [last observation carried forward (LOCF)] CGAS score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
End point timeframe:	
Baseline, 10 weeks	

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	123	124		
Units: units on a scale				
least squares mean (standard error)	17.14 (\pm 1.232)	12.16 (\pm 1.219)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants During the 10-Week Period with Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

End point title	Percentage of Participants During the 10-Week Period with Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
-----------------	--

End point description:

The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any 1 of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Results reported as percentage of participants with treatment-emergent (new or worsening) suicidal ideation from baseline=(number of participants with changes compared to baseline/total number of participants at risk)*100.

Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline C-SSRS suicidal ideation score during the acute treatment period, whose baseline maximum C-SSRS suicidal ideation score was <5. Nine (9) participants from 1 site with major quality issues were excluded.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 10 weeks

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	134		
Units: percentage of participants				
number (not applicable)	5.9	5.2		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants During the 10-Week Period with Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

End point title	Percentage of Participants During the 10-Week Period with Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
-----------------	--

End point description:

The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Reported as percentage of participants with treatment-emergent (new or worsening) suicidal behavior from baseline=(number of participants with changes compared to baseline/total number of participants at risk)*100.

Analysis Population Description: Randomized participants with a baseline and at least 1 post-baseline C-SSRS suicidal behavior score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 10 weeks

End point values	Duloxetine (Acute Treatment)	Placebo (Acute Treatment)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	135	134		
Units: percentage of participants				
number (not applicable)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from 10-Week to 28-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist

End point title	Change from 10-Week to 28-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist
-----------------	---

End point description:

PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline*visit, and age category*visit within reporting groups.

Analysis Population Description: Randomized participants with a PARS severity score for GAD during the acute treatment period and at least 1 PARS severity score for GAD during the extension treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
----------------	-----------

End point timeframe:

10 weeks, 28 weeks

End point values	Duloxetine/Duloxetine	Placebo/Duloxetine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	105		
Units: units on a scale				
least squares mean (standard error)	-3.33 (\pm 0.352)	-5.15 (\pm 0.452)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from 10-Week to 28-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom ChecklistSymptoms

End point title	Change from 10-Week to 28-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom ChecklistSymptoms
-----------------	---

End point description:

PARS severity total score was assessed for all symptoms identified on the PARS symptom checklist. PARS severity total score was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity total scores ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline*visit, and age category*visit within reporting groups.

Analysis Population Description: Randomized participants with a PARS severity total score during the acute treatment period and at least 1 PARS severity total score during the extension treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
----------------	-----------

End point timeframe:

10 weeks, 28 weeks

End point values	Duloxetine/Duloxetine	Placebo/Duloxetine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	105		
Units: units on a scale				
least squares mean (standard error)	-3.32 (\pm 0.357)	-5.26 (\pm 0.432)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from 10-Week to 28-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale

End point title	Change from 10-Week to 28-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale
End point description:	
The CGI-S scale evaluated the severity of mental illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline*visit, and age category*visit within reporting groups.	
Analysis Population Description: Randomized participants with a CGI-S score during the acute treatment period and at least 1 CGI-S score during the extension treatment period, excluding 9 participants from 1 site with major quality issues.	
End point type	Secondary
End point timeframe:	
10 weeks, 28 weeks	

End point values	Duloxetine/Duloxetine	Placebo/Duloxetine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	105		
Units: units on a scale				
least squares mean (standard error)	-0.76 (± 0.093)	-1.17 (± 0.088)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from 10-Week to 28-Week Endpoint in the Children's Global Assessment Scale (CGAS)

End point title	Change from 10-Week to 28-Week Endpoint in the Children's Global Assessment Scale (CGAS)
End point description:	
The CGAS was a clinician-rated assessment of general functioning. CGAS raw scores ranged from 1 (greatest impairment) to 100 (superior functioning). Lower scores indicated a lower level of functioning and greater impairment. Least squares (LS) mean from an analysis of covariance (ANCOVA) was adjusted for pooled investigator, baseline, and age category within reporting groups.	
Analysis Population Description: Randomized participants with a CGAS score during the acute treatment period and at least 1 CGAS score during the extension treatment period [last observation carried forward (LOCF)], excluding 9 participants from 1 site with major quality issues.	
End point type	Secondary
End point timeframe:	
10 weeks, 28 weeks	

End point values	Duloxetine/Duloxetine	Placebo/Duloxetine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	103	105		
Units: units on a scale				
least squares mean (standard error)	7.32 (\pm 1.19)	10.48 (\pm 1.03)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants During the 18-Week Extension Period with Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

End point title	Percentage of Participants During the 18-Week Extension Period with Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
-----------------	--

End point description:

The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any 1 of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Results reported as percentage of participants with treatment-emergent (new or worsening) suicidal ideation from baseline=(number of participants with changes compared to baseline/total number of participants at risk)*100.

Analysis Population Description: Randomized participants with a C-SSRS suicidal ideation score <5 at the last 2 visits in the acute treatment period and at least 1 C-SSRS suicidal ideation score during the extension treatment period. Nine (9) participants from 1 site with major quality issues were excluded.

End point type	Secondary
End point timeframe:	
10 weeks up to 28 weeks	

End point values	Duloxetine/Duloxetine	Placebo/Duloxetine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	105		
Units: percentage of participants				
number (not applicable)	3	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants During the 18-Week Extension Period with Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

End point title	Percentage of Participants During the 18-Week Extension Period with Treatment-Emergent (New or Worsening) Suicidal
-----------------	--

End point description:

The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Reported as percentage of participants with treatment-emergent (new or worsening) suicidal behavior from baseline=(number of participants with changes compared to baseline/total number of participants at risk)*100.

Analysis Population Description: Randomized participants with a C-SSRS suicidal behavior score at the last 2 visits in the acute treatment period and at least 1 C-SSRS suicidal behavior score during the extension treatment period, excluding 9 participants from 1 site with major quality issues.

End point type	Secondary
End point timeframe:	
10 weeks up to 28 weeks	

End point values	Duloxetine/Duloxetine	Placebo/Duloxetine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	105		
Units: percentage of participants				
number (not applicable)	0	2		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

F1J-MC-HMGI

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

Reporting groups

Reporting group title	Duloxetine-Acute
-----------------------	------------------

Reporting group description:

Adverse events (AEs) during the acute treatment period for participants who received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks.

Reporting group title	Placebo-Acute
-----------------------	---------------

Reporting group description:

AEs during the acute treatment period for participants who received placebo capsules orally, QD for 10 weeks.

Reporting group title	Duloxetine-Extension
-----------------------	----------------------

Reporting group description:

AEs during the extension treatment period for participants who received flexible doses of duloxetine 30 to 120 mg orally, QD during both the acute and extension treatment periods (up to 28 weeks).

Reporting group title	Placebo/Duloxetine-Extension
-----------------------	------------------------------

Reporting group description:

AEs during the extension treatment period for participants who received placebo capsules orally, QD during the acute treatment period (10 weeks) and flexible doses of duloxetine 30 to 120 mg orally, QD during the extension treatment period (up to 18 weeks).

Reporting group title	Duloxetine-Taper
-----------------------	------------------

Reporting group description:

AEs during the taper period for participants who were dispensed duloxetine prior to entering the taper phase.

Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period.

Reporting group title	Placebo-Taper
-----------------------	---------------

Reporting group description:

AEs during the taper period for participants who were dispensed placebo prior to entering the taper phase.

Participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.

Serious adverse events	Duloxetine-Acute	Placebo-Acute	Duloxetine-Extension
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	2 / 104 (1.92%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Psychiatric disorders			

acute psychosis alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bipolar disorder alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
self-injurious ideation alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicidal ideation alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
adenoiditis alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tonsillitis alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo/Duloxetine- Extension	Duloxetine-Taper	Placebo-Taper
Total subjects affected by serious			

adverse events			
subjects affected / exposed	2 / 106 (1.89%)	1 / 97 (1.03%)	1 / 7 (14.29%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Psychiatric disorders			
acute psychosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bipolar disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
self-injurious ideation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicidal ideation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 97 (1.03%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
adenoiditis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tonsillitis			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Duloxetine-Acute	Placebo-Acute	Duloxetine-Extension
Total subjects affected by non-serious adverse events			
subjects affected / exposed	106 / 135 (78.52%)	90 / 137 (65.69%)	73 / 104 (70.19%)
Vascular disorders			
hot flush			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	2	1	0
hypotension			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	2
pallor			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
Surgical and medical procedures			
tooth extraction			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	2	1	0
chest discomfort			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	0	1	1
chest pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 135 (2.22%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	3	0	1
crying			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
fatigue			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	11 / 135 (8.15%)	6 / 137 (4.38%)	4 / 104 (3.85%)
occurrences (all)	11	6	4
feeling abnormal			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
feeling cold			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
inflammation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
inflammatory pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
influenza like illness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0

irritability			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 135 (2.96%)	6 / 137 (4.38%)	4 / 104 (3.85%)
occurrences (all)	4	6	4
malaise			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
medical device pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
non-cardiac chest pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
oedema peripheral			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	0	1	1
pyrexia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	4 / 137 (2.92%)	2 / 104 (1.92%)
occurrences (all)	2	5	2
temperature intolerance			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
thirst			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	1 / 137 (0.73%) 1	0 / 104 (0.00%) 0
Immune system disorders multiple allergies alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	1 / 104 (0.96%) 1
seasonal allergy alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	0 / 137 (0.00%) 0	2 / 104 (1.92%) 2
Social circumstances educational problem alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	1 / 137 (0.73%) 1	0 / 104 (0.00%) 0
Reproductive system and breast disorders breast mass alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
dysmenorrhoea alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[1] occurrences (all)	2 / 70 (2.86%) 3	2 / 75 (2.67%) 2	0 / 104 (0.00%) 0
orchitis noninfective alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[2] occurrences (all)	0 / 135 (0.00%) 0	1 / 62 (1.61%) 1	0 / 104 (0.00%) 0
ovarian cyst alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[3] occurrences (all)	1 / 70 (1.43%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
vaginal haemorrhage alternative dictionary used: MedDRA 16.0			

subjects affected / exposed ^[4]	1 / 70 (1.43%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
asthma			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	2	0	0
cough			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	6 / 135 (4.44%)	0 / 137 (0.00%)	4 / 104 (3.85%)
occurrences (all)	6	0	4
dyspnoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 135 (2.22%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	3	0	0
epistaxis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	2 / 104 (1.92%)
occurrences (all)	4	1	2
nasal congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	1	1	1
oropharyngeal pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	10 / 135 (7.41%)	3 / 137 (2.19%)	1 / 104 (0.96%)
occurrences (all)	10	3	1
pharyngeal inflammation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
productive cough			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
respiratory tract congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
rhinitis allergic			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	1	1	0
rhinorrhoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
sinus congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	1	1	0
yawning			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
abnormal behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	2	0	0
abnormal dreams			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	2	1	0
activation syndrome			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
affect liability			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
aggression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	2 / 137 (1.46%)	1 / 104 (0.96%)
occurrences (all)	1	2	1
agitation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	2	1	0
anger			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
anxiety			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
apathy			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
attention deficit/hyperactivity disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
bruxism			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0

compulsive handwashing			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
depression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
distractibility			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
fear			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
flat affect			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
impulsive behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	2 / 104 (1.92%)
occurrences (all)	0	0	2
initial insomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	1	1	0
insomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	12 / 135 (8.89%)	7 / 137 (5.11%)	1 / 104 (0.96%)
occurrences (all)	13	8	1
intentional self-injury			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	3 / 104 (2.88%)
occurrences (all)	1	1	3
Major depression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
middle insomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	2	1	0
negativism			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
nervousness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
nightmare			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	2	0	0
obsessive thoughts			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
onychophagia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
oppositional defiant disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0

panic attack			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	2	0
phobia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
psychotic disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
self injurious behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
sexually inappropriate behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
sleep disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	2 / 137 (1.46%)	0 / 104 (0.00%)
occurrences (all)	1	2	0
sleep terror			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
suicidal ideation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	2 / 104 (1.92%)
occurrences (all)	1	1	3
tic			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	1	1	0
withdrawal syndrome			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
Investigations			
blood pressure increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
blood triglycerides increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
electrocardiogram qt prolonged			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
heart rate increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	2	1	0
neutrophil count increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
weight decreased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 135 (3.70%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	5	1	0
weight increased			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	2 / 135 (1.48%)	3 / 137 (2.19%)	2 / 104 (1.92%)
occurrences (all)	2	3	2
white blood cell count increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
animal bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
ankle fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
arthropod bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
arthropod sting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
bone contusion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
burns first degree			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
concussion			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
fall			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
fibula fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
head injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
human bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
humerus fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
joint dislocation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
laceration			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
ligament sprain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	2 / 104 (1.92%)
occurrences (all)	0	0	2

limb injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	2	1	1
lip injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
muscle rupture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
muscle strain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	1	1	1
post procedural swelling			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
procedural pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
road traffic accident			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
scratch			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
sunburn			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
tendon injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
thermal burn			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
upper limb fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
bundle branch block right			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
palpitations			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	6 / 135 (4.44%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	6	0	0
sinus arrhythmia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
sinus tachycardia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
tachycardia			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	1 / 104 (0.96%) 1
Nervous system disorders			
disturbance in attention			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	2	1	1
dizziness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	10 / 135 (7.41%)	2 / 137 (1.46%)	5 / 104 (4.81%)
occurrences (all)	10	2	5
dizziness postural			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
dysgeusia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
dyskinesia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
headache			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	27 / 135 (20.00%)	23 / 137 (16.79%)	13 / 104 (12.50%)
occurrences (all)	37	29	17
hypersomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	1	1	1
hypoesthesia			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	2 / 104 (1.92%)
occurrences (all)	0	0	2
migraine			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	2 / 137 (1.46%)	1 / 104 (0.96%)
occurrences (all)	0	2	1
myoclonus			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
paraesthesia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	3 / 137 (2.19%)	0 / 104 (0.00%)
occurrences (all)	0	3	0
poor quality sleep			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
post-traumatic headache			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
psychomotor hyperactivity			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 135 (2.22%)	2 / 137 (1.46%)	1 / 104 (0.96%)
occurrences (all)	3	2	1
sedation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 135 (2.22%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	3	0	0
somnolence			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	16 / 135 (11.85%)	9 / 137 (6.57%)	3 / 104 (2.88%)
occurrences (all)	16	9	4

tremor alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	4 / 135 (2.96%) 4	1 / 137 (0.73%) 1	2 / 104 (1.92%) 2
Ear and labyrinth disorders			
ear pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	2 / 137 (1.46%) 2	0 / 104 (0.00%) 0
motion sickness alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
tinnitus alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	1 / 137 (0.73%) 1	0 / 104 (0.00%) 0
vertigo alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
Eye disorders			
blepharospasm alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
blindness alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
conjunctival haemorrhage alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
eye pain			

<p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 135 (0.00%)</p> <p>0</p>	<p>0 / 137 (0.00%)</p> <p>0</p>	<p>0 / 104 (0.00%)</p> <p>0</p>
<p>mydriasis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 135 (1.48%)</p> <p>2</p>	<p>0 / 137 (0.00%)</p> <p>0</p>	<p>0 / 104 (0.00%)</p> <p>0</p>
<p>strabismus</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 135 (0.74%)</p> <p>1</p>	<p>0 / 137 (0.00%)</p> <p>0</p>	<p>0 / 104 (0.00%)</p> <p>0</p>
<p>vision blurred</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 135 (0.00%)</p> <p>0</p>	<p>0 / 137 (0.00%)</p> <p>0</p>	<p>0 / 104 (0.00%)</p> <p>0</p>
<p>Gastrointestinal disorders</p> <p>abdominal discomfort</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 135 (2.22%)</p> <p>3</p>	<p>4 / 137 (2.92%)</p> <p>4</p>	<p>0 / 104 (0.00%)</p> <p>0</p>
<p>abdominal distension</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 135 (0.74%)</p> <p>1</p>	<p>1 / 137 (0.73%)</p> <p>2</p>	<p>1 / 104 (0.96%)</p> <p>1</p>
<p>abdominal pain</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 135 (1.48%)</p> <p>2</p>	<p>0 / 137 (0.00%)</p> <p>0</p>	<p>2 / 104 (1.92%)</p> <p>2</p>
<p>abdominal pain lower</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 135 (0.00%)</p> <p>0</p>	<p>2 / 137 (1.46%)</p> <p>2</p>	<p>0 / 104 (0.00%)</p> <p>0</p>
<p>abdominal pain upper</p> <p>alternative dictionary used: MedDRA 16.0</p>			

subjects affected / exposed	13 / 135 (9.63%)	9 / 137 (6.57%)	5 / 104 (4.81%)
occurrences (all)	15	10	6
aphthous stomatitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
chapped lips			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
colitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
constipation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 135 (3.70%)	4 / 137 (2.92%)	0 / 104 (0.00%)
occurrences (all)	6	4	0
diarrhoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	9 / 135 (6.67%)	6 / 137 (4.38%)	1 / 104 (0.96%)
occurrences (all)	10	6	3
dry mouth			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	2	2	1
dyspepsia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	2 / 104 (1.92%)
occurrences (all)	0	0	2
eructation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	1	1	1

flatulence			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
food poisoning			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
frequent bowel movements			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
gastritis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	1	1	0
gastroesophageal reflux disease			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
gingival pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
lip dry			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	1	1	0
mouth ulceration			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
nausea			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	28 / 135 (20.74%)	8 / 137 (5.84%)	10 / 104 (9.62%)
occurrences (all)	35	8	10
odynophagia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
oral mucosal blistering			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
toothache			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	2 / 104 (1.92%)
occurrences (all)	0	0	2
vomiting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	22 / 135 (16.30%)	10 / 137 (7.30%)	5 / 104 (4.81%)
occurrences (all)	23	10	7
Skin and subcutaneous tissue disorders			
acne			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	2	0	1
alopecia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
dermatitis allergic			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
dermatitis contact			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	2 / 104 (1.92%)
occurrences (all)	2	0	2
dry skin			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
erythema			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
hyperhidrosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 135 (2.22%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	4	2	1
night sweats			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
petechiae			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
pruritus			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	0	4	1
rash			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	2 / 137 (1.46%)	1 / 104 (0.96%)
occurrences (all)	1	2	1
rash maculo-papular			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0

rash papular alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	0 / 137 (0.00%) 0	1 / 104 (0.96%) 1
rash pruritic alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
urticaria alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	1 / 137 (0.73%) 1	0 / 104 (0.00%) 0
Renal and urinary disorders enuresis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
hypertonic bladder alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	1 / 137 (0.73%) 1	0 / 104 (0.00%) 0
pollakiuria alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
urinary hesitation alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
Endocrine disorders hypothyroidism alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
Musculoskeletal and connective tissue disorders			

arthralgia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	2	0	0
back pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	2	0	0
bone pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
flank pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
muscle spasms			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
muscle twitching			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
musculoskeletal pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
myalgia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	2	0	0
neck pain			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
pain in extremity			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	2 / 104 (1.92%)
occurrences (all)	1	2	2
synovial cyst			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
temporomandibular joint syndrome			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 135 (2.96%)	4 / 137 (2.92%)	2 / 104 (1.92%)
occurrences (all)	4	4	2
conjunctivitis infective			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
ear infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	2 / 137 (1.46%)	3 / 104 (2.88%)
occurrences (all)	1	2	3
fungus infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	0 / 104 (0.00%)
occurrences (all)	0	1	0
gastroenteritis			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 135 (0.74%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	1	1	1
gastroenteritis viral			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 135 (2.96%)	2 / 137 (1.46%)	1 / 104 (0.96%)
occurrences (all)	4	2	1
gastrointestinal infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
gastrointestinal viral infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
genital candidiasis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
hand-foot-and-mouth disease			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
herpes simplex			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
hordeolum			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
influenza			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 135 (2.96%)	3 / 137 (2.19%)	6 / 104 (5.77%)
occurrences (all)	4	3	6

labyrinthitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
lower respiratory tract infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
nasopharyngitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 135 (2.96%)	12 / 137 (8.76%)	4 / 104 (3.85%)
occurrences (all)	4	13	4
oral herpes			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
otitis externa			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
otitis media			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
pharyngitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 135 (2.22%)	1 / 137 (0.73%)	2 / 104 (1.92%)
occurrences (all)	3	1	2
pharyngitis streptococcal			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	2 / 137 (1.46%)	3 / 104 (2.88%)
occurrences (all)	1	2	3
pharyngotonsillitis			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 135 (0.74%)	2 / 137 (1.46%)	1 / 104 (0.96%)
occurrences (all)	1	2	1
pneumonia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	0	1	1
rhinitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	1 / 137 (0.73%)	1 / 104 (0.96%)
occurrences (all)	0	1	1
sinusitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	4 / 137 (2.92%)	6 / 104 (5.77%)
occurrences (all)	1	4	6
skin infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	1	0	0
staphylococcal infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	0 / 104 (0.00%)
occurrences (all)	0	0	0
tonsillitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 135 (0.74%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	1	0	1
tooth infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 135 (0.00%)	0 / 137 (0.00%)	1 / 104 (0.96%)
occurrences (all)	0	0	1
upper respiratory tract infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 135 (1.48%)	4 / 137 (2.92%)	3 / 104 (2.88%)
occurrences (all)	2	4	4

urinary tract infection alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	2 / 137 (1.46%) 2	3 / 104 (2.88%) 3
vaginitis bacterial alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[5] occurrences (all)	1 / 70 (1.43%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
viral infection alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	2 / 137 (1.46%) 2	0 / 104 (0.00%) 0
viral upper respiratory tract infection alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 135 (0.74%) 1	0 / 137 (0.00%) 0	0 / 104 (0.00%) 0
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	20 / 135 (14.81%) 21	7 / 137 (5.11%) 7	1 / 104 (0.96%) 1
dehydration alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	0 / 137 (0.00%) 0	1 / 104 (0.96%) 1
increased appetite alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 135 (1.48%) 2	4 / 137 (2.92%) 4	0 / 104 (0.00%) 0

Non-serious adverse events	Placebo/Duloxetine- Extension	Duloxetine-Taper	Placebo-Taper
Total subjects affected by non-serious adverse events			
subjects affected / exposed	73 / 106 (68.87%)	12 / 97 (12.37%)	1 / 7 (14.29%)
Vascular disorders			

hot flush alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 3	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
hypotension alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
pallor alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Surgical and medical procedures tooth extraction alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
General disorders and administration site conditions asthenia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	1 / 97 (1.03%) 1	0 / 7 (0.00%) 0
chest discomfort alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
chest pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
crying alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	1 / 97 (1.03%) 1	0 / 7 (0.00%) 0
fatigue			

alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	9 / 106 (8.49%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	9	0	0
feeling abnormal			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
feeling cold			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
inflammation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
inflammatory pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
influenza like illness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
irritability			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 106 (2.83%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	3	1	0
malaise			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
medical device pain			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
non-cardiac chest pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
oedema peripheral			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
pyrexia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
temperature intolerance			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
thirst			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
multiple allergies			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
seasonal allergy			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Social circumstances educational problem alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Reproductive system and breast disorders breast mass alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all) dysmenorrhoea alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[1] occurrences (all) orchitis noninfective alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[2] occurrences (all) ovarian cyst alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[3] occurrences (all) vaginal haemorrhage alternative dictionary used: MedDRA 16.0 subjects affected / exposed ^[4] occurrences (all)	0 / 106 (0.00%) 0 2 / 59 (3.39%) 2 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0	0 / 97 (0.00%) 0 0 / 97 (0.00%) 0 0 / 97 (0.00%) 0 0 / 97 (0.00%) 0 0 / 97 (0.00%) 0 0 / 97 (0.00%) 0	0 / 7 (0.00%) 0 0 / 7 (0.00%) 0 0 / 7 (0.00%) 0 0 / 7 (0.00%) 0 0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders asthma alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all) cough alternative dictionary used:	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0

MedDRA 16.0			
subjects affected / exposed	5 / 106 (4.72%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	5	0	0
dyspnoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
epistaxis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
nasal congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
oropharyngeal pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	7 / 106 (6.60%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	7	0	0
pharyngeal inflammation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
productive cough			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
respiratory tract congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
rhinitis allergic			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
rhinorrhoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
sinus congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
yawning			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	3	0	0
Psychiatric disorders			
abnormal behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
abnormal dreams			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
activation syndrome			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
affect lability			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
aggression			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
agitation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
anger			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
anxiety			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
apathy			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
attention deficit/hyperactivity disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
bruxism			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
compulsive handwashing			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
depression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

distractibility			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
fear			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
flat affect			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
impulsive behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
initial insomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
insomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 106 (2.83%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	3	0	0
intentional self-injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Major depression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
middle insomnia			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
negativism			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
nervousness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
nightmare			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
obsessive thoughts			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
onychophagia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
oppositional defiant disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
panic attack			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
phobia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

psychotic disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
self injurious behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
sexually inappropriate behaviour			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
sleep disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
sleep terror			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
suicidal ideation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
tic			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
withdrawal syndrome			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Investigations			

blood pressure increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
blood triglycerides increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
electrocardiogram qt prolonged alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
heart rate increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
neutrophil count increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
weight decreased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
weight increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
white blood cell count increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications			

animal bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
ankle fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
arthropod bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
arthropod sting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
bone contusion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
burns first degree			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
concussion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
fall			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
fibula fracture			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
head injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
human bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
humerus fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
joint dislocation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
laceration			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
ligament sprain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	2	1	0
limb injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
lip injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

muscle rupture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
muscle strain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
post procedural swelling			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
procedural pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
road traffic accident			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
scratch			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
sunburn			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
tendon injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
thermal burn			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
upper limb fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
bundle branch block right			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
palpitations			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
sinus arrhythmia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
sinus tachycardia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
tachycardia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
disturbance in attention			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
dizziness			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	7 / 106 (6.60%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	9	1	0
dizziness postural			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
dysgeusia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
dyskinesia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
headache			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	11 / 106 (10.38%)	3 / 97 (3.09%)	0 / 7 (0.00%)
occurrences (all)	13	3	0
hypersomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
hypoaesthesia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
migraine			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
myoclonus			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

paraesthesia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	1 / 97 (1.03%) 1	0 / 7 (0.00%) 0
poor quality sleep alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
post-traumatic headache alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
psychomotor hyperactivity alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
sedation alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
somnolence alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	8 / 106 (7.55%) 11	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
tremor alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	1 / 97 (1.03%) 1	0 / 7 (0.00%) 0
Ear and labyrinth disorders ear pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all) motion sickness alternative dictionary used: MedDRA 16.0	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
tinnitus			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
vertigo			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Eye disorders			
blepharospasm			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
blindness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
conjunctival haemorrhage			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
eye pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
mydriasis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
strabismus			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
vision blurred			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
abdominal discomfort			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
abdominal distension			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
abdominal pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
abdominal pain lower			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
abdominal pain upper			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	7 / 106 (6.60%)	2 / 97 (2.06%)	0 / 7 (0.00%)
occurrences (all)	7	2	0
aphthous stomatitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
chapped lips			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
colitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	3	0	0
constipation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
diarrhoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 106 (4.72%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	6	0	0
dry mouth			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
dyspepsia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
eructation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
flatulence			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
food poisoning			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

frequent bowel movements			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
gastritis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
gastroesophageal reflux disease			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
gingival pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
lip dry			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
mouth ulceration			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
nausea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	13 / 106 (12.26%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	16	1	0
odynophagia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
oral mucosal blistering			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
toothache			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
vomiting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	6 / 106 (5.66%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	6	0	0
Skin and subcutaneous tissue disorders			
acne			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
alopecia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
dermatitis allergic			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
dermatitis contact			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
dry skin			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
erythema			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
hyperhidrosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	4	0	0
night sweats			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
petechiae			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
pruritus			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	4	0	0
rash			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 106 (3.77%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	4	0	0
rash maculo-papular			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
rash papular			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
rash pruritic			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

urticaria alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders enuresis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 5	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
hypertonic bladder alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
pollakiuria alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
urinary hesitation alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Endocrine disorders hypothyroidism alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	1 / 97 (1.03%) 2	0 / 7 (0.00%) 0
back pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0

bone pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
flank pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
muscle spasms			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
muscle twitching			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
musculoskeletal pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
myalgia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
neck pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
pain in extremity			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
synovial cyst			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
temporomandibular joint syndrome			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
conjunctivitis infective			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
ear infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
fungal infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
gastroenteritis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 106 (2.83%)	1 / 97 (1.03%)	0 / 7 (0.00%)
occurrences (all)	3	1	0
gastroenteritis viral			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
gastrointestinal infection			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
gastrointestinal viral infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
genital candidiasis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
hand-foot-and-mouth disease			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
herpes simplex			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
hordeolum			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
influenza			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 106 (3.77%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	4	0	0
labyrinthitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
lower respiratory tract infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

nasopharyngitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 106 (4.72%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	5	0	0
oral herpes			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
otitis externa			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
otitis media			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
pharyngitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
pharyngitis streptococcal			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
pharyngotonsillitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
pneumonia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
rhinitis			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
sinusitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 106 (4.72%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	5	0	0
skin infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
staphylococcal infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
tonsillitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
tooth infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
urinary tract infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
vaginitis bacterial			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed ^[5]	0 / 106 (0.00%)	0 / 97 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

viral infection alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
viral upper respiratory tract infection alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	9 / 106 (8.49%) 10	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
dehydration alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0
increased appetite alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 97 (0.00%) 0	0 / 7 (0.00%) 0

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific event, total number exposed corresponds to only female subjects.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific event, total number exposed corresponds to only male subjects.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific event, total number exposed corresponds to only female subjects.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific event, total number exposed corresponds to only female subjects.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific event, total number exposed corresponds to only female subjects.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 February 2011	Dose range was changed based on health authority recommendation.
31 July 2012	Statistical analysis sample size was changed.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

All Randomized participants from one site were excluded due to major quality issues at site; they were not considered part of ITT population and were excluded from the subject disposition, baseline characteristics, efficacy and safety analyses.

Notes: